Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech has demonstrated significant growth, with sales of surgical soft tissue repair products increasing by 24% year-over-year to $23.4 million, driven by heightened demand for its CellerateRX Surgical product. The company is also on track for sustainable revenue growth, anticipating topline growth of 3-5% in 2025 and an impressive 13-17% in 2026, supported by a lucrative contract with Vizient that enhances access to its BIASURGE product line. Additionally, Sanara's operational improvements and strategic partnerships, including an Innovative Technology contract with Vizient, position the company for continued financial success and enhanced market presence in the wound care sector.

Bears say

Sanara MedTech Inc reported net revenue of $26.3 million, which reflects a year-over-year growth of 21.5%, although this figure fell short of the projected revenue of $26.7 million. The company faces multiple risks that may adversely affect its financial performance, including lower-than-expected revenue growth, challenges in acquiring new customers, difficulties in launching new products or services, and potential dilution risks. Additionally, there has been a significant reduction in the company's enterprise value to revenue multiple from 4.3x to 3.0x, driven by the exclusion of telehealth from its business model, indicating a shift in market perception and potential valuation concerns.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.